Tigecycline

Manufactured by Biosynth

Sourced in United States, France, United Kingdom

Tigecycline is a broad-spectrum antibiotic used in the treatment of various bacterial infections. It functions as a protein synthesis inhibitor, preventing the growth and proliferation of bacteria. Tigecycline is commonly used in clinical settings to manage complicated infections.

Automatically generated - may contain errors

Lab products found in correlation

Meropenem, by Biosynth (2 mentions) Amikacin, by Biosynth (2 mentions) 4 hydroxytamoxifen, by Merck Group (1 mentions) Sodium l ascorbate, by Merck Group (1 mentions) L buthionine sulfoximine, by Merck Group (1 mentions) N acetyl l cysteine, by Merck Group (1 mentions) Deferoxamine mesylate, by Merck Group (1 mentions) Ciprofloxacin, by Biosynth (1 mentions) Kanamycin, by Merck Group (1 mentions) Bbl mueller hinton 2 broth, by BD (1 mentions) Mueller hinton agar (mha), by Thermo Fisher Scientific (1 mentions)

3 protocols using tigecycline

Redox Modulation in Cancer Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

IACS‐010759 (from the Institute for Applied Cancer Science at MD Anderson; Molina et al, 2018 (link)) and 4‐hydroxytamoxifen (Merck Life Science, Darmstadt, Germany) were dissolved in DMSO and ethanol, respectively; sodium L‐ascorbate, N‐acetyl‐L‐cysteine (NAC), L‐buthionine sulfoximine, 6‐aminonicotinamide, deferoxamine mesylate (Merck Life Science), dehydroepiandrosterone (Cayman Chemical Co., Ann Arbor, MI, USA), and tigecycline (Carbosynth, Newbury, UK) were dissolved in water.
GSH/GSSG and NADPH/NADP were quantified with luminescence‐based assay kits (Promega, Madison, WI, USA) and the enzymatic activities of G6pd and Pgd with colorimetric assay kits (BioVision/Abcam, Waltham, MA, USA), according to manufacturer's specifications.

Donati G., Nicoli P., Verrecchia A., Vallelonga V., Croci O., Rodighiero S., Audano M., Cassina L., Ghsein A., Binelli G., Boletta A., Mitro N, & Amati B. (2023). Oxidative stress enhances the therapeutic action of a respiratory inhibitor in MYC‐driven lymphoma. EMBO Molecular Medicine, 15(6), e16910.

+ Open protocol

+ Expand

Antibacterial Activity Evaluation Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

NOSO-502 was synthesized at Nosopharm, Nîmes, France (Biosynth, ref: AC20542), ciprofloxacin (Biosynth, ref: AC58172), meropenem (Biosynth, ref: AM32026), ceftazidime-avibactam (CAZ: Biosynth, ref: AC19871; AVI: Biosynth, ref: AA158833), tigecycline (Biosynth, ref: AT10818), and amikacin (CAZ: Biosynth, ref: AA17356) were obtained from manufacturers as standard powders. The BBL Mueller-Hinton II Broth (Becton, Dickinson, ref: 212322), alone or with 1.4% wt/wt agarose (Grosseron ref A8963) and the Mueller-Hinton Agar (Oxoid, ref CM0337) were used in all experiments. When necessary, Mueller-Hinton was supplemented with kanamycin at 40 μg/mL (Sigma-Aldrich, ref: K1637).

Pantel L., Guérin F., Serri M., Gravey F., Houard J., Maurent K., Attwood M., Noel A., MacGowan A., Racine E., Cattoir V, & Gualtieri M. (2022). Exploring Cluster-Dependent Antibacterial Activities and Resistance Pathways of NOSO-502 and Colistin against Enterobacter cloacae Complex Species. Antimicrobial Agents and Chemotherapy, 66(11), e00776-22.

+ Open protocol

+ Expand

Antibacterial Drug Susceptibility Testing

Check if the same lab product or an alternative is used in the 5 most similar protocols

Minimal inhibitory concentration (MIC) values of the commercially available antibacterial drugs ceftriaxone, cefepime, meropenem, levofloxacin, amikacin, and tigecycline and DFO for 55 Gram-negative isolates included in our study were determined with broth microdilution methods according to EUCAST standards (ISO 20776-1:2019). Stock solutions of ceftriaxone, cefepime, meropenem, levofloxacin, amikacin, and tigecycline (Carbosynth, Campton, UK) were prepared in accordance with the manufacturer's instructions. Water was utilized as a solvent for ceftriaxone, meropenem, levofloxacin, amikacin, and tigecycline. The solvent for cefepime was phosphate buffer (pH 6.0, 0.1 mol/L). Twofold concentrations of antibiotics and DFO ranging between 0.06 µg/mL and 64 µg/mL (from 0.06 µg/mL to 512 µg/mL for DFO) were added to microplate wells filled with cation-adjusted Mueller-Hinton broth (CAMHB). Bacterial suspension at the concentration of 5×10 CFU/mL was inoculated to the microplate wells. Inoculated microplates were incubated at 35 ±2°C for 24 h. The MIC was defined as the lowest antimicrobial drug concentration that inhibits the visible growth of the microorganism in the microdilution wells.

Erinmez M, & Zer Y. (2024). In vitro effects of deferoxamine on antibiotic susceptibility in Gram-negative bacteria. Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 33(5).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!